Overview

This is a prospective, open-label, one-arm study. The study aims to assess the efficacy and safety of Etanercept therapy which help guide the clinical practice in real-world settings.

Eligibility

Inclusion Criteria:

        1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of
        psoriasis≥6 months 4.Patients must be candidate for systemic therapy or phototherapy 5.No
        contradiction to Etanercept 6.Informed consent must be obtained 7.For female, ß-hCG test is
        negative and contraception is accepted
        Exclusion Criteria:
          1. Diagnosis of pustular psoriasis, erythroderma psoriasis or drug-induced psoriasis
          2. Having severe infections, including hepatitis, HIV and tuberculosis
          3. No live vaccines 12 weeks before enrollment, through the study and 1 year after the
             last dose of Etanercept
          4. Having significant allergies to biological agents
          5. Having the previous experience of biologics
          6. Having a history of malignancy
          7. Having contradictions to Etanercept
          8. Refusal of contraception
          9. Having serious or unstable/uncontrolled illnesses